Targeting amyloid aggregation: an overview of strategies and mechanisms

S Giorgetti, C Greco, P Tortora, FA Aprile - International journal of …, 2018 - mdpi.com
Amyloids result from the aggregation of a set of diverse proteins, due to either specific
mutations or promoting intra-or extra-cellular conditions. Structurally, they are rich in …

Machado–Joseph disease/spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapy

CA Matos, LP de Almeida… - Journal of …, 2019 - Wiley Online Library
Abstract Machado–Joseph disease (MJD), also known as spinocerebellar ataxia type 3
(SCA 3), is an incurable disorder, widely regarded as the most common form of …

Preclinical activities of epigallocatechin gallate in signaling pathways in cancer

M Sharifi-Rad, R Pezzani, M Redaelli, M Zorzan… - Molecules, 2020 - mdpi.com
Epigallocatechin gallate (EGCG) is the main bioactive component of catechins
predominantly present in various types of tea. EGCG is well known for a wide spectrum of …

Potential therapeutic use of plant flavonoids in AD and PD

S Meng-Zhen, L Ju, Z Lan-Chun, D Cai-Feng… - Heliyon, 2022 - cell.com
Background Millions of people suffer from Alzheimer's disease (AD) and Parkinson's
disease (PD) worldwide. Due to their complex pathology, no effective pharmacological …

[HTML][HTML] Neurotheranostics as personalized medicines

BD Kevadiya, BM Ottemann, MB Thomas… - Advanced Drug Delivery …, 2019 - Elsevier
The discipline of neurotheranostics was forged to improve diagnostic and therapeutic
clinical outcomes for neurological disorders. Research was facilitated, in largest measure …

The green tea polyphenolic catechin epigallocatechin gallate and neuroprotection

AR Khalatbary, E Khademi - Nutritional neuroscience, 2020 - Taylor & Francis
Epigallocatechin gallate is the most abundant composition of the tea catechins and is
thought to be responsible for the majority of biological activity of green tea extracts such as …

Caenorhabditis elegans as a model system for target identification and drug screening against neurodegenerative diseases

L Ma, Y Zhao, Y Chen, B Cheng, A Peng… - European Journal of …, 2018 - Elsevier
Over the past decades, Caenorhabditis elegans (C. elegans) has been widely used as a
model system because of its small size, transparent body, short generation time and lifespan …

Protein misfolding and aggregation as a therapeutic target for polyglutamine diseases

T Takeuchi, Y Nagai - Brain sciences, 2017 - mdpi.com
The polyglutamine (polyQ) diseases, such as Huntington's disease and several types of
spinocerebellar ataxias, are a group of inherited neurodegenerative diseases that are …

GST-4-Dependent Suppression of Neurodegeneration in C. elegans Models of Parkinson's and Machado-Joseph Disease by Rapeseed Pomace Extract …

F Pohl, A Teixeira-Castro, MD Costa… - Frontiers in …, 2019 - frontiersin.org
Genetic mutations and aging-associated oxidative damage underlie the onset and
progression of neurodegenerative diseases, like Parkinson's disease (PD) and Machado …

Protein aggregation inhibitors as disease-modifying therapies for polyglutamine diseases

EN Minakawa, Y Nagai - Frontiers in neuroscience, 2021 - frontiersin.org
The polyglutamine (polyQ) diseases are a group of inherited neurodegenerative diseases
caused by the abnormal expansion of a CAG trinucleotide repeat that are translated into an …